雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Immunological evaluation of personalized peptide vaccination for patients with advanced malignant glioma Naoki Yajima 1 , Ryuya Yamanaka 1 , Ryuichi Tanaka 1 , Takashi Mine 2 , Kyogo Itoh 2 1Department of Neurosurgery, Brain Research Institute, Niigata University 2Department of Immunology, and Research Center of Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University School of Medicine Keyword: 免疫療法 , 個別化ペプチドワクチン , 悪性脳腫瘍 pp.927-929
Published Date 2005/12/10
DOI https://doi.org/10.11477/mf.1431100115
  • Abstract
  • Look Inside

Purpose:The primary goal of this phaseⅠ study was to assess the safety and immunological responses of personalized peptide vaccination for patients with advanced malignant glioma.

 Experimental Design:Twenty-five patients with advanced malignant glioma(8 grade 3 and 17 grade 4 gliomas)were evaluated in a phaseⅠ clinical study of a personalized peptide vaccination. For personalized peptide vaccination, pre-vaccination peripheral blood mononuclear cells and plasma were provided to examine cellular and humoral responses to 25 or 23 peptides in HLA-A24+ or HLA-A2+ patients, respectively, and then only the reactive peptides(maximum:4)were used for in vivo administration.

 Results:The protocols were well tolerated with local redness and swelling at the injection site in most cases. Twenty-one patients received more than six vaccinations and were evaluated for both immunological and clinical responses. Increases in cellular or humoral responses specific to at least one of the vaccinated peptides was observed in the post-vaccination(6th)-samples from 14 or 11 of 21 patients, respectively. More importantly, significant levels of peptide-specific IgG were detected in the post-vaccination tumor cavity or spinal fluid of all of the tested patients who showed favorable clinical responses. Clinical responses were 5 partial responses, 8 cases of stable disease, and 8 cases of progressive disease. The median overall survival for patients with recurrent glioblastoma multiforme in this study(n=17)was 622 days.

 Conclusions:Personalized peptide vaccinations were recommended for the further clinical study to malignant glioma patients.


Copyright © 2005, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1243 印刷版ISSN 0001-8724 医学書院

関連文献

もっと見る

文献を共有